DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key
word(s): Final Results/Dividend
Eckert & Ziegler fiscal year 2013: slight decrease in sales. Proposed
dividend unchanged. Optimistic for fiscal year 2014.
27.03.2014 / 07:45
---------------------------------------------------------------------
Berlin, March 27, 2014. Eckert & Ziegler Strahlen- und Medizintechnik AG
(ISIN DE0005659700), a Berlin-based company specializing in isotope
technology for medical, scientific and industrial applications, reported
sales of EUR 117.1 million in 2013 (previous year: EUR 120.0 million). The
decisive factors for this development were the decline in sales in
industrial components, implants and instruments, the planned exit from the
accessories trade in France as well as the unfavorable EUR/USD exchange
rate. Additional sales from acquisitions were unable to compensate for
these effects.
Consolidated net profit after taxes and minority interests fell by 12% from
EUR 10.3 million to EUR 9.1 million, and earnings per share dropped EUR
0.23/share to EUR 1.72. The main reason for this was the decline in the
gross margin, which was down 12% due to one-off effects although sales only
registered a 2% decline. Higher sales costs as a result of higher one time
waste costs as well as a shift in the product mix to low-margin products
were also responsible.
A sales breakdown by segment shows the following sales distribution:
The Radiation Therapy segment reported the largest nominal decline in sales
of EUR 3.9 million to EUR 27.8 million. Special sales in the previous year
from a one-off license fee for the use of Company patents and technologies
in Russia and the discontinuation of the radiation accessories business in
France were the two factors responsible for this. Adjusted for these
effects, sales in the Radiation Therapy segment grew in particular on the
back of stable demand for tumor irradiation equipment (+7%).
Sales in the Isotope Products segment contracted 4% to EUR 54 million due
to the lower demand for industrial components in China and America as well
as unfavorable exchange rate effects.
Sales in the Radiopharma segment increased by EUR 2.3 million or 9%. This
was largely a result of the acquisition of Austrian company BSM Diagnostica
GmbH, which contributed EUR 3.0 million to sales.
A foreign acquisition also significantly contributed to sales growth in the
Environmental Services segment at EUR 1.6 million. Sales increased EUR 1.1
million or 18% on the back of the first-time inclusion of the British waste
management business acquired from Energy Solutions.
Overall, sales and earnings are expected to see at least 10% growth in
fiscal year 2014. This corresponds to sales of some EUR 129 million and net
profit of around EUR 10 million (EPS approx. EUR 1.90/share) for the year.
Internal planning figures are considerably higher than these threshold
values.
The complete annual financial statements can be viewed under:
http://www.ezag.com/home/investors/financial-reports.html
The Executive Board and Supervisory Board will propose to the Annual
General Meeting on May 22, 2014, a dividend of EUR 0.60 per share entitled
to a dividend (previous year: EUR 0.60).
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with
approximately 700 employees, is one the world's largest providers of
isotope technology for radiation therapy and nuclear medicine.
Contributing to saving lives.
For further information or questions, please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de
End of Corporate News
---------------------------------------------------------------------
27.03.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, Düsseldorf, Hamburg, München
End of News DGAP News-Service
---------------------------------------------------------------------
259824 27.03.2014
DGAP-News: Eckert & Ziegler fiscal year 2013: slight decrease in sales. Proposed dividend unchanged. Optimistic for fiscal year 2014.
| Source: EQS Group AG